NYSE:AIMAIM ImmunoTech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.99 +0.07 (+2.40 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$2.82Now: $2.99▼$3.1050-Day Range$2.35MA: $2.75▼$3.8852-Week Range$0.38Now: $2.99▼$7.11Volume6.54 million shsAverage Volume8.85 million shsMarket Capitalization$97.53 millionP/E RatioN/ADividend YieldN/ABeta-0.83 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, AIM ImmunoTech has a potential upside of 50.5% from its current price of $2.99.Amount of Analyst CoverageAIM ImmunoTech has only been the subject of 1 research reports in the past 90 days. Previous Next 3.3 Community Rank Outperform VotesAIM ImmunoTech has received 48 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAIM ImmunoTech has received 25 “underperform” votes. (Add your “underperform” vote.)Community SentimentAIM ImmunoTech has received 65.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AIM ImmunoTech and other stocks. Vote “Outperform” if you believe AIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AIM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.96% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by InstitutionsOnly 1.74% of the stock of AIM ImmunoTech is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioAIM ImmunoTech has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:AIM Previous Symbol CUSIPN/A CIKN/A Webaimimmuno.com Phone352-448-7797Debt Debt-to-Equity Ratio0.19 Current Ratio42.26 Quick Ratio42.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales696.67 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book2.03Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-9,530,000.00 Net Margins-5,392.43% Return on Equity-61.52% Return on Assets-40.34%Miscellaneous Employees31 Outstanding Shares32,620,000Market Cap$97.53 million Next Earnings Date8/20/2020 (Estimated) OptionableNot Optionable $2.99 +0.07 (+2.40 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AIM News and Ratings via Email Sign-up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. AIM ImmunoTech (NYSE:AIM) Frequently Asked Questions How has AIM ImmunoTech's stock been impacted by COVID-19 (Coronavirus)? AIM ImmunoTech's stock was trading at $4.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AIM shares have decreased by 28.8% and is now trading at $2.99. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AIM ImmunoTech? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AIM ImmunoTech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AIM ImmunoTech. When is AIM ImmunoTech's next earnings date? AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for AIM ImmunoTech. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) released its earnings results on Wednesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.13. The firm had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative return on equity of 61.52% and a negative net margin of 5,392.43%. View AIM ImmunoTech's earnings history. What price target have analysts set for AIM? 2 equities research analysts have issued 12 month price targets for AIM ImmunoTech's shares. Their forecasts range from $4.00 to $5.00. On average, they expect AIM ImmunoTech's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 50.5% from the stock's current price. View analysts' price targets for AIM ImmunoTech. Has AIM ImmunoTech been receiving favorable news coverage? Media stories about AIM stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AIM ImmunoTech earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about AIM ImmunoTech. Who are some of AIM ImmunoTech's key competitors? Some companies that are related to AIM ImmunoTech include Precision BioSciences (DTIL), Harpoon Therapeutics (HARP), Cabaletta Bio (CABA), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), DBV TECHNOLOGIE/S (DBVT), ADMA Biologics (ADMA), Dyadic International (DYAI), Pluristem Therapeutics (PSTI), CASI Pharmaceuticals (CASI), Fennec Pharmaceuticals (FENC), Sutro Biopharma (STRO), GENFIT S A/ADR (GNFT), Axcella Health (AXLA) and LogicBio Therapeutics (LOGC). View all competitors. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Vaxart (VXRT), SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Ibio (IBIO), Novavax (NVAX), Canopy Growth (CGC), Pfizer (PFE) and Nokia Oyj (NOK). Who are AIM ImmunoTech's key executives? AIM ImmunoTech's management team includes the following people: Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)Mr. Adam Pascale, Consultant (Age 71)Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)Ms. Ellen Lintal, Chief Accounting Officer What is AIM ImmunoTech's stock symbol? AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM." Who are AIM ImmunoTech's major shareholders? AIM ImmunoTech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.20%), SeaCrest Wealth Management LLC (0.14%) and Stanley Laman Group Ltd. (0.04%). Company insiders that own AIM ImmunoTech stock include David R Strayer, Thomas K Equels, Wayne S Springate and William M Mitchell. View institutional ownership trends for AIM ImmunoTech. Which institutional investors are buying AIM ImmunoTech stock? AIM stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, SeaCrest Wealth Management LLC, and Stanley Laman Group Ltd.. Company insiders that have bought AIM ImmunoTech stock in the last two years include David R Strayer, Thomas K Equels, Wayne S Springate, and William M Mitchell. View insider buying and selling activity for AIM ImmunoTech. How do I buy shares of AIM ImmunoTech? Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AIM ImmunoTech's stock price today? One share of AIM stock can currently be purchased for approximately $2.99. How big of a company is AIM ImmunoTech? AIM ImmunoTech has a market capitalization of $97.53 million and generates $140,000.00 in revenue each year. AIM ImmunoTech employs 31 workers across the globe. What is AIM ImmunoTech's official website? The official website for AIM ImmunoTech is aimimmuno.com. How can I contact AIM ImmunoTech? AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company can be reached via phone at 352-448-7797 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
